Dose Prediction for
Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis
Rajith K. R. Rajoli1, Henry
Pertinez1, Usman Arshad1, Helen
Box1, Lee Tatham1, Paul
Curley1, Megan Neary1, Joanne
Sharp1, Neill J. Liptrott1, Anthony
Valentijn1, Christopher David1,
Steve P. Rannard2, Ghaith
Aljayyoussi3, Shaun H. Pennington3,
Andrew Hill1, Marta Boffito4,5,
Stephen A. Ward3, Saye H. Khoo1,
Patrick G. Bray6, Paul M. O’Neill2,
W. Dave Hong2, Giancarlo Biagini3,
Andrew Owen1.
1Department of Molecular and Clinical Pharmacology,
Materials Innovation Factory, University of Liverpool, Liverpool, L7
3NY, UK
2Department of Chemistry, University of Liverpool,
Liverpool, L69 3BX, UK
3Centre for Drugs and Diagnostics, and Department of
Tropical Disease Biology, Liverpool School of Tropical Medicine,
Liverpool L3 5QA, UK
4Chelsea and Westminster NHS Foundation Trust and St
Stephen’s AIDS Trust 4th Floor, Chelsea and Westminster Hospital, 369
Fulham Road, London, SW10 9NH, UK
5Jefferiss Research Trust Laboratories, Department of
Medicine, Imperial College, London, W2 1PG, UK
6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan,
WN5 8QZ, UK